Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Steroid Biochem Mol Biol. 2016 Sep 13;173:139–147. doi: 10.1016/j.jsbmb.2016.09.009

Fig 5.

Fig 5

Reduced BRAF expression impedes BIM expression and cell death enhancement by D2/CA in patients AML blasts ex vivo. A. BRAF mRNA increases in the three treatment groups, but this is significantly reduced by siBRAF. Repeated RT-PCR determinations were performed on a sample taken from one patient. B. BIM protein increases when ex vivo cells are treated with AraC or with AraC-D2/CA, but this is inhibited by siBRAF. C. Cell death determinations by Trypan blue permeability, or D, by Annexin V flow cytometry, show that cell death difference (ie the enhancement of cytotoxicity) between treatment group 4 minus group 3, are reduced in both patients studied when BRAF expression is reduced by siBRAF (group 8 minus group 7). *=p<0.01 compared to control group; #=p<0.01 compared to AraC treated group; ◆=p<0.01 compared to corresponding siControl group, n= 3.